The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.

Albert GrinshpunSara M TolaneyHarold J BursteinRinath M JeselsohnErica L Mayer
Published in: NPJ breast cancer (2023)